EC Number   |
|---|
   3.4.17.20 | - |
| 3.4.17.20 | development of a method to isolate in situ activated TAFIa from human serum in presence of epsilon-aminocaproic acid |
| 3.4.17.20 | development of a method to isolate in situ activated TAFIa from serum in presence of epsilon-aminocaproic acid |
| 3.4.17.20 | from plasma |
| 3.4.17.20 | from plasma by a plasminogen affinity based method |
| 3.4.17.20 | native pro-CPU from human plasma by two steps of ion exchange chromatography, plasminogen affinity chromatography, gel filtration, and anion exchange chromatography, recombinant pro-CPU from Sf21 and H5 insect cells using the same method as for the native enzyme, to homogeneity |
| 3.4.17.20 | of cloned enzyme from BHK-cells |
| 3.4.17.20 | purified by chromatography on Q-Sepharose Fast Flow, Heparin-Sepharose CL-6B, Sephacryl S-300, and plasminogen-Sepharose columns |
| 3.4.17.20 | purified from plasma using a ECH-lysine sepharose column and anion-exchange chromatography |
| 3.4.17.20 | recombinant enzyme and mutant enzyme R302Q |
